SUICIDALITY AND ANTIDEPRESSANT DRUGS
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of SEROQUEL or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL is not approved for use in patients under ten years of age [see Warnings and Precautions
SEROQUEL® (quetiapine fumarate) is a psychotropic agent belonging to a chemical class, the dibenzothiazepine derivatives.
SEROQUEL is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL in schizophrenia was established in three 6-week trials in adults and one 6week trial in adolescents (1317 years). The effectiveness of SEROQUEL for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see Clinical Studies ].
SEROQUEL is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10-17 years) [ see Clinical Studies
SEROQUEL is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies
SEROQUEL is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of SEROQUEL as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials [ see Clinical Studies
Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder
Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.
Media Articles Related to Seroquel (Quetiapine)
First physiological test for schizophrenia and depression
Source: Depression News From Medical News Today [2017.03.15]
Researchers have found a new way of using proteins in nerve cells to identify people with depression and schizophrenia.
Major research project provides new clues to schizophrenia
Source: Psychology / Psychiatry News From Medical News Today [2017.03.15]
Researchers at Karolinska Institutet collaborating in the large-scale Karolinska Schizophrenia Project are taking an integrative approach to unravel the disease mechanisms of schizophrenia.
Blood Test Might Someday Distinguish Early Depression, Schizophrenia
Source: MedicineNet Depression Specialty [2017.03.15]
Title: Blood Test Might Someday Distinguish Early Depression, Schizophrenia
Category: Health News
Created: 3/14/2017 12:00:00 AM
Last Editorial Review: 3/15/2017 12:00:00 AM
Changes in RNA splicing: A new mechanism for genetic risk in schizophrenia
Source: Schizophrenia News From Medical News Today [2017.03.01]
New research has identified sections of DNA associated with altered regulation of gene expression underlying schizophrenia.
Pitt bioinformatics study provides clues to relationship between schizophrenia and rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2017.02.28]
An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid arthritis by researchers at the University of Pittsburgh points to eight genes that may...
Published Studies Related to Seroquel (Quetiapine)
Predicting 1-year risk for relapse in patients who have discontinued or continued
quetiapine after remission from first-episode psychosis. 
CONCLUSION: Different predictors of relapse were identified for first episode
Quetiapine versus haloperidol in the treatment of delirium: a double-blind,
randomized, controlled trial. 
delirious behavior... CONCLUSION: Low-dose quetiapine and haloperidol may be equally effective and safe
Annual cost of relapses and relapse-related hospitalizations in adults with
schizophrenia: results from a 12-month, double-blind, comparative study of
lurasidone vs quetiapine extended-release. 
quetiapine extended-release (XR)... CONCLUSION: Adults treated for schizophrenia with lurasidone are predicted to
Randomized, placebo-controlled trial of quetiapine XR and divalproex ER
monotherapies in the treatment of the anxious bipolar patient. 
are seldom the focus of bipolar treatment studies... CONCLUSIONS: Quetiapine XR in a dose range of 50-300 mg/day appears to reduce
Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. 
This article briefly summarizes the burden of bipolar disorder and the clinical
profile of quetiapine (Seroquel®) in the management of bipolar disorder, followed
by a detailed review of pharmacoeconomic analyses...
Clinical Trials Related to Seroquel (Quetiapine)
Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) [Active, not recruiting]
The Primary objective of this study is to evaluate Seroquel XR in the treatment of BPD. As
in many initial RCTs, the study will be of relatively short duration - 8 weeks - to assess
effectiveness and safety while maximizing retention. The specific aim is to determine if
Seroquel XR is superior to placebo. The primary outcome measure will be a statistically
significant difference between Seroquel XR compared to placebo on the ZAN-BPD, an objective
rating scale that addresses the severity of DSM-IV symptoms of the illness. As there is the
recent development of an extended release form of Seroquel (Seroquel XR) (Schulz et al.
2007), the new compound may offer several advantages in this study. Therefore, the
hypothesis of this study is that both doses of Seroquel XR (see below) will be superior to
placebo in an 8-week randomized trial as assessed by the ZAN-BPD.
To achieve the Primary Objective of this study, two doses of Seroquel XR will be tested -
150 mg/d and 300 mg/d. Thus, the study will be able to assess the effect of Seroquel XR
compared to placebo and to explore a dose effect.
Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia [Completed]
The primary objective of the study is to assess the relative efficacy of Depakote ER and
Seroquel for agitated behaviors among veterans with a dementia diagnosis residing in a
Department of Veterans Affairs (VA) nursing home care unit (NHCU). The secondary objective
of the study is to assess the relative tolerability of Depakote ER and Seroquel in this
population. The primary hypothesis is that agitated dementia patients will demonstrate a
significantly greater reduction in Cohen-Mansfield Agitation Inventory (CMAI) scores while
treated with Depakote ER compared to treatment with Seroquel.
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms [Terminated]
The purpose of this study is to compare the efficacy and tolerability of Seroquel
monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus
Selective Serotonin Reuptake Inhibitor.
Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania [Recruiting]
The goal of this research is to evaluate the safety as well as effectiveness of Utapine and
Seroquel in bipolar I disorder patients.
Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine [Active, not recruiting]
Quetiapine, a second generation antipsychotic, is only available as oral tablets. However,
topical and rectal formulations have been produced in compounding pharmacies. There is no
data available suggesting that topical or rectal formulations provide serum levels similar
to oral medication. In the clinical setting, when oral administration of quetiapine is not
possible (for example, when a patient is extremely ill physically or mentally or both),
clinicians and pharmacists have collaborated in such cases and have at times had to
administer quetiapine compounded in other dosage formulations such as rectal or topical
formulations. Despite clinical effectiveness of these "other" formulations, there
are no available studies that have investigated blood levels of the drug other than the oral
form. The investigators are therefore designing this pharmacokinetic study to evaluate the
the systemic absorption of quetiapine in oral, rectal and topical formulations. If the
investigators are able to demonstrate detectable levels from rectal and topical quetiapine
formulations compared to the oral form, this knowledge will enhance clinical psychiatric
practice by providing a more broad route of administration for quetiapine which is a
commonly used drug for psychiatric symptoms.
Reports of Suspected Seroquel (Quetiapine) Side Effects
Drug Dose Omission (1904),
OFF Label USE (1165),
Intentional Drug Misuse (531),
Feeling Abnormal (471),
Weight Increased (389), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 32 ratings/reviews, Seroquel has an overall score of 6. The effectiveness score is 7.69 and the side effect score is 5.69. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Seroquel review by 45 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || schizo-affective disorder|
|Dosage & duration:|| || 200mg taken once daily at bedtime for the period of 2 yrs|
|Other conditions:|| || high cholesterol|
|Other drugs taken:|| || none|
|Benefits:|| || A very good nights sleep is one of the benefits, found out that the sedative effects are actually increased in the lower doses. I lowered my dosage and live the sound sleep. it knocked out my delusions and hallucinations, hopefully for good.|
|Side effects:|| || weight gain is the worst side effect, but a small price to pay for sanity.|
|Comments:|| || I actually ended up with motion disorders from all the other meds, the worst one being parkinsons for over a year. I had to take parkinsons drugs. It was so scary drooling all the time and looking stone faced, no expression. I dont feel any signs of this with the seroquel.|
Seroquel review by 38 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || bipolar mania|
|Dosage & duration:|| || 50 mg taken as needed for the period of 2 years|
|Other conditions:|| || bipolar depression, anxiety|
|Other drugs taken:|| || lamictal|
|Benefits:|| || I am using this on an as needed basis. I only take it a couple times a month, which is why 50mg still works for me. I may have to go to 100mg though. If I have been up for 20-25 hours straight and if I am still "bouncing off the walls" (manic), then this is great stuff to have.
For as needed manic episodes and severe insomnia--this is great stuff.|
|Side effects:|| || Biggest problem is the LONG half-half. After sleeping for over 10 hours, I spend the next 6 hours after I wake up foggy-headed and VERY lethargic. After this I usually feel good again.|
|Comments:|| || I mainly suffer from severe depression and anxiety but after a couple weeks of this I sometimes suffer from 2 or 3 days of mania. |
Seroquel review by 20 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Marginally Effective|
|Side effects:|| || Extremely Severe Side Effects|
|Condition / reason:|| || Bi-polar, depression|
|Dosage & duration:|| || 100mg taken once a day for the period of 5 months|
|Other conditions:|| || N/A|
|Other drugs taken:|| || N/A|
|Benefits:|| || For the first two months it seemed to help, even though the first night on it was the scariest feeling ever. It made me motivated for those two months..|
|Side effects:|| || I ended up with severe anxiety and paranoia after taking this pill, something I had never had before taking it. After the initial 2 month honeymoon period, I felt like I was a zombie..I literally felt nothing at all, and if I was lucky enough to feel something, it would be anxiety. I'm STILL trying to reverse the effects of this drug, and I've been off it for over 3 years now. I would not recommend this to ANYONE, unless you're willing to ruin your personality & life for the sake of a two month good spell.|
|Comments:|| || .|
Page last updated: 2017-03-15